Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00ZCU
|
||||
Former ID |
DIB019041
|
||||
Drug Name |
BW723C86
|
||||
Synonyms |
BW-72386
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [538986] | ||
Structure |
Download2D MOL |
||||
Formula |
C16H18N2OS
|
||||
InChI |
InChI=1S/C16H18N2OS/c1-11(17)7-12-9-18-16-5-4-13(8-15(12)16)19-10-14-3-2-6-20-14/h2-6,8-9,11,18H,7,10,17H2,1H3
|
||||
InChIKey |
ALFGDCNSEBJYSP-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 2C receptor | Target Info | Agonist | [526719] | |
5-hydroxytryptamine 2B receptor | Target Info | Agonist | [526719] | ||
5-hydroxytryptamine 2A receptor | Target Info | Agonist | [527178] | ||
WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
SIDS Susceptibility Pathways | |||||
GPCR downstream signaling | |||||
GPCRs, Other | |||||
References | |||||
Ref 526719 | Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003 Sep;140(2):277-84. Epub 2003 Aug 11. | ||||
Ref 527178 | Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. Epub 2004 Jul 30. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.